Industry
Biotechnology
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of treatment for patients suffering from debilitating neurodegenerative diseases. Its lead product, PrimeC, is a novel oral formulation that has completed Phase IIa clinical trials for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.
Loading...
Open
0.91
Mkt cap
18M
Volume
276K
High
0.94
P/E Ratio
-1.30
52-wk high
2.33
Low
0.81
Div yield
N/A
52-wk low
0.51
Portfolio Pulse from
December 04, 2024 | 1:45 pm
Portfolio Pulse from
December 02, 2024 | 1:45 pm
Portfolio Pulse from
November 21, 2024 | 2:30 pm
Portfolio Pulse from Benzinga Newsdesk
October 28, 2024 | 12:00 pm
Portfolio Pulse from Vandana Singh
October 28, 2024 | 12:00 pm
Portfolio Pulse from Benzinga Newsdesk
October 28, 2024 | 12:00 pm
Portfolio Pulse from Benzinga Newsdesk
October 28, 2024 | 12:00 pm
Portfolio Pulse from Benzinga Newsdesk
October 15, 2024 | 1:24 pm
Portfolio Pulse from Benzinga Newsdesk
October 09, 2024 | 1:07 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.